# Ractigen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ractigen-therapeutics

- Industry: Biotechnology
- Headquarters: Nantong, China
- Website: www.ractigen.com
- Total disclosed funding: $48M
- Latest round: Series A (Jan 27, 2022)
- Investors on record: 9

## About

Based in Nantong, China, and founded in 2016, China US Zhongmei Ruikang Nucleic Acid Technology (Nantong) Research Institute Co., Ltd., trading as Ractigen Therapeutics, develops RNA activation (RNAa)-based therapeutics and gene expression technologies for the treatment of genetic and other diseases. In July 2026, Ractigen Therapeutics raised over CNY 200 million in venture funding led by Shenzhen Guozhong Venture Capital, with participation from IDG Capital, China Everbright, Jolmo Capital, SND Ventures Group, Puying Group, Zhuhai Longmen Capital Management, and other investors.

The company provides innovative gene medicines and disease treatments for many fields, such as tumors, liver targets, and the central nervous system. The company focuses on ribonucleic acid (RNA) activation technology. RNA technology can restart the expression of endogenous genes and restore proteins's natural function to treat disease. The company's product pipeline includes monogenetic disease products RAG-06, oncology products RAG-01, skin condition products RAG-11, and liver disease products RAG-03. The company develops the Smart-TTC and SCAD technology platforms.

The company generates revenue by developing and commercializing RNA activation-based therapeutics, drug candidates, and related genetic medicine technologies.

The venture funding raised in July 2026 will primarily be used to accelerate the clinical advancement of its core pipelines, including RAG-17 (ALS) and RAG-01 (bladder cancer), to advance RAG-18 (Duchenne muscular dystrophy) and metabolic projects into clinical INDs, and to upgrade its globally unique saRNA/siRNA dual-modality platform and extrahepatic delivery system.

## Funding rounds

- Series A, Jan 27, 2022, $31M — LC Ventures, SDIC Venture Capital, Eisai, China-Singapore Suzhou Industrial Park Development Group, Xianghe Capital
- Series A, Feb 11, 2021, $17M — CCB International, Zhuhai Longmen Capital Management, Chongqing Boyi Equity Investment Fund Management, GL Ventures

## Investors

- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Chongqing Boyi Equity Investment Fund Management — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- LC Ventures (https://capitalatlas.ai/funds/lc-ventures) — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Eisai — Series A
- China-Singapore Suzhou Industrial Park Development Group — Series A
- Xianghe Capital — Series A